GLP-1GLP-1 1981P K LundGlucagonP K Lund., 19811983G I Bell-1GLP-1-2GLP-2G I Bell., 1983 L O UttenthalGLPL O Uttenthal., 1985M VarndellGLPI M Varndell., 19851986C OrskovGLP-1GLP-2C Orskov., 1986 GLP-1M GhiglioneGLP-1M Ghiglione., 1984W E SchmidtGLP-1W E Schmidt19851987J J HolstGLP-17-36GLP-1GLP-17-36IncretinJ J Holst1987C OrskovGLP-1GLP-17-36C Orskov., 1987B Kreymann GLP-17-36GIPB Kreymann., 1987 1988T Matsuyama GLP-1T Matsuyama.1988GLP-1 1989G C WeirGLP-17-37GLP-17-36GLP-1G C Weir., 1989 GLP-1GLP-1 1989B T SchjoldagerGLP-17-36B T Schjoldager., 19891993A WettergrenGLP-17-36A Wettergren., 19931996M D TurtonGLP-1GLP-1GLP-1M D Turton., 1996 GLP-1GLP-1 1993R MentleinGLP-17-36-4DDP-4N2R Mentlein.,1993GLP-1DDP-42.4 PPT Copyright 2020 ICP18041379-3
The Revolutionary Role of GLP-1 Agonists and SGLT-2 Inhibitors in Managing Diabetes and Chronic Kidney Disease in Liver Transplant Recipients
& Bar-Sagi, D
SGLT2is and NAFLD/NASH risk Although the exact mechanisms of the hepatic effect of SGLT2i therapy remain unclear, several possible hypotheses have been proposed to support the decreased risk of NAFLD following this treatment
These negative regulators act in different ways to suppress JAKSTAT signaling
Zhu Y, Sun J, Zhu Y, Wang L, Qi B (2015) Endogenic oxidative stress response contributes to glutathione over-accumulation in mutant Saccharomyces cerevisiae Y518
